- Injection 300 mg/mL
Suppresses bacterial protein synthesis.
Following IM administration, average C max is 11.6 mcg/mL at 60 min and therapeutic levels are maintained for 17 to 20 h for most susceptible gram-positive organisms. Following a 2-hour IV infusion, average C max is approximately 16 mcg/mL and therapeutic levels are maintained for 14 h for most susceptible gram-positive organisms.
Urinary excretion following IM and IV administration ranges from 1.8% to 24.8% and 4.9% to 30.3%, respectively. The t ½ is 5.4 h. Biliary excretion is an important route of elimination.
Special PopulationsRenal Function Impairment
Serum t ½ may be prolonged in patients with severe renal function impairment.Hepatic Function Impairment
Serum t ½ may be 2-fold longer in patients with abnormal hepatic function.
Indications and Usage
Treatment of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. Reserve use for patients in whom penicillin is inappropriate.
Hypersensitivity to lincomycin or clindamycin.
Dosage and AdministrationAdults
IV For serious infections, administer 600 to 1,000 mg every 8 to 12 h. For more severe infections, the dose may be increased. In life-threatening infections, doses up to 8 g/day have been given (max, 8 g/day).Children older than 1 mo of age
IV 10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection; administer in divided doses.Adults
IM For serious infections, administer 600 mg every 24 h. For more severe infections, 600 mg every 12 h or more often.Children older than 1 mo of age
IM For serious infections, administer 10 mg/kg (5 mg/lb) every 24 h. For more severe infections, 10 mg/kg (5 mg/lb) every 12 h or more often.Adults
Subconjunctival 75 mg (0.25 mL)Severe Renal Function Impairment
Adults and Children older than 1 mo of age
IV / IM Appropriate dose is 25% to 30% of that recommended for patients with healthy renal function.
- IV concentration and rate: 600 to 1,000 mg: Use 100 mL of diluent and administer over a period of not less than 1 h. 2 g: Use 200 mL of diluent and administer over a period of not less than 2 h. 3 g: Use 300 mL of diluent and administer over a period of not less than 3 h. 4 g: Use 400 mL of diluent and administer over a period of not less than 4 h.
Store at 68° to 77°F.
Drug InteractionsAluminum salts
GI absorption of lincomycin may be decreased and delayed.Erythromycin
May cause antagonism.Neuromuscular blocking agents
May enhance the effects of neuromuscular blocking agents.
Laboratory Test Interactions
None well documented.
Cardiopulmonary arrest and hypotension following too rapid IV administration.
Erythema multiforme; exfoliative and vesiculobullous dermatitis; rash; Stevens-Johnson syndrome; urticaria.
Colitis; diarrhea; glossitis; nausea; pruritus ani; pseudomembranous colitis; stomatitis; vomiting.
Azotemia; oliguria; proteinuria; vaginitis.
Agranulocytosis; aplastic anemia; leukopenia; neutropenia; pancytopenia; thrombocytopenic purpura.
Abnormal LFT (particularly serum transaminase); jaundice.
Anaphylaxis; angioneurotic edema; serum sickness.
Lincomycin can cause Clostridium difficile –associated diarrhea (CDAD), which may range in severity from mild diarrhea to fatal colitis. Hypertoxin-producing strains of C. difficile can be refractory to antimicrobial therapy and may require colectomy. Consider CDAD in all patients presenting with diarrhea following lincomycin use; it may occur later than 2 mo after therapy. Promptly manage cases by administering appropriate fluids, electrolytes, protein supplementation, and antibiotic treatment.
Monitor patients, especially elderly patients, for changes in bowel frequency. Perform periodic hepatic and renal function tests and blood cell counts.
Category C .
Excreted in breast milk.
Safety and efficacy not established in children younger than 1 mo of age.
May be more susceptible to changes in bowel frequency.
Serum t ½ may be prolonged in patients with severe renal function impairment. Use with caution.
Serum t ½ may be 2-fold longer in patient with abnormal hepatic function. Use with caution.
Special Risk Patients
Use with caution in patients with a history of asthma, significant allergies, or GI disease, particularly colitis
May result in bacterial, fungal, or yeast overgrowth of nonsusceptible organisms.
Serious anaphylactoid reactions requiring immediate emergency treatment may occur.
Sterile solution contains benzyl alcohol as a preservative, which has been associated with fatal gasping syndrome in premature infants.
May occur when the drug is administered at greater than the recommended concentration and rate.
Drug levels in the CSF may be inadequate for the treatment of meningitis.
- Instruct patients to contact health care provider as soon as possible if watery or bloody stools occur.
- Instruct patients not to stop taking this medicine, even if they start to feel better.
Copyright © 2009 Wolters Kluwer Health.
More Lincomycin resources
- Lincomycin Prescribing Information (FDA)
- lincomycin Concise Consumer Information (Cerner Multum)
- lincomycin Oral, Injection Advanced Consumer (Micromedex) - Includes Dosage Information
- lincomycin MedFacts Consumer Leaflet (Wolters Kluwer)
- Lincocin Monograph (AHFS DI)
- Lincocin Prescribing Information (FDA)